Eli Lilly will build a $6 billion new facility in Huntsville, Ala., to manufacture active pharmaceutical ingredients for small molecule and peptide medicines, including the company’s oral GLP-1 candidate, orforglipron.
The site will support domestic production of therapies and strengthen pharmaceutical supply chains, according to a Dec. 9 news release from the drugmaker. The project is expected to create 450 full-time jobs and 3,000 construction roles. Construction will begin in 2026, with completion expected in 2032.
Eli Lilly selected the location in part for its proximity to the HudsonAlpha Institute for Biotechnology, which supports bioscience workforce development. The company plans to embed artificial intelligence, digital automation and data analytics throughout the site.
The Alabama project follows recently announced expansions in Texas, Virginia, and Puerto Rico. A fourth new U.S. location is expected to be named in the coming weeks, according to the release.
